TROP2-CAR-NK (University of Texas MD Anderson Cancer Center)

TROP2-CAR-NK is an investigational cell-based immunotherapy developed by The University of Texas MD Anderson Cancer Center. The therapy consists of cord blood-derived natural killer (NK) cells that have been genetically engineered using a retroviral vector to express a chimeric antigen receptor (CAR) targeting Trophoblast cell-surface antigen 2 (TROP2). The CAR construct incorporates a humanized single-chain variable fragment (scFv) derived from the hRS7 antibody, along with optimized co-stimulatory domains. To enhance cell persistence and anti-tumor activity, the cells are further modified to express membrane-bound Interleukin-15 (IL-15). Additionally, an inducible caspase-9 (iC9) safety switch is included to allow for the rapid elimination of the cells in the event of severe toxicity. Designed as an off-the-shelf product, TROP2-CAR-NK is currently being evaluated in Phase I/II clinical trials for intraperitoneal administration in patients with platinum-resistant ovarian cancer, mesonephric-like adenocarcinoma, and pancreatic cancer.

Other names

TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK CellsTROP-2 CAR Engineered IL15-transduced Cord Blood-derived NK CellsTROP 2 CAR Engineered IL15-transduced Cord Blood-derived NK CellsTROP2-CAR-NK-M.D. Anderson Cancer CenterTROP-2-CAR-NK-M.D. Anderson Cancer CenterTROP 2-CAR-NK-M.D. Anderson Cancer Center